J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sakarcan, A
Right arrow Articles by Marino, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sakarcan, A
Right arrow Articles by Marino, M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Articles

The pharmacokinetics of irbesartan in hypertensive children and adolescents

A Sakarcan, F Tenney, JT Wilson, JJ Stewart, KG Adcock, TG Wells, NN Vachharajani, OW Hadjilambris, P Slugg, NF Ford, and MR Marino

An open-label study was conducted to characterize the pharmacokinetics and antihypertensive response to irbesartan in children (1-12 years) and adolescents (13-16 years) with hypertension. Patients received single once-daily oral doses of irbesartan 2 mg/kg (maximum of 150 mg once daily) for 2 to 4 weeks (+/- nifedipine or hydrochlorothiazide). Plasma irbesartan concentrations were determined by a validated high-performance liquid chromatography/fluorescence method from blood samples taken predose, up to 24 hours after dosing on Day 1, and up to 48 hours after the final dose. The plasma concentration-time profiles were similar between the 6- to 12-year and the 13- to 16-year age groups and to that previously determined from a study of adult subjects receiving approximately 2 mg/kg (i.e., 150 mg) oral irbesartan once daily. Mean reductions in systolic/diastolic blood pressure were 16/10 mmHg at Day 28 with irbesartan monotherapy (n = 8). Irbesartan was well tolerated and may be a treatment option for pediatric hypertensive patients.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
A. M Franks, C. E O'Brien, C. D Stowe, T. G Wells, and S. F Gardner
Candesartan Cilexetil Effectively Reduces Blood Pressure in Hypertensive Children
Ann. Pharmacother., October 1, 2008; 42(10): 1388 - 1395.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
D. K. Benjamin Jr, P. B. Smith, P. Jadhav, J. V. Gobburu, M. D. Murphy, V. Hasselblad, C. Baker-Smith, R. M. Califf, and J. S. Li
Pediatric Antihypertensive Trial Failures: Analysis of End Points and Dose Range
Hypertension, April 1, 2008; 51(4): 834 - 840.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
National High Blood Pressure Education Program Wor
The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents
Pediatrics, August 1, 2004; 114(2/S2): 555 - 576.
[Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
S. F Gardner and A. M Franks
Olmesartan Medoxomil: The Seventh Angiotensin Receptor Antagonist
Ann. Pharmacother., January 1, 2003; 37(1): 99 - 105.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the American College of Clinical Pharmacology